| | Publication Year | Title | Author(s) |
| 1 | 30-Jan-2024 | Implementation of a nurse-led, multidisciplinary model of care for older adults with cancer: a process evaluation protocol. | Dufton, Polly Hypatia; Tarasenko, Elena; Midgley, Katrina; Lee, Kathryn; Kelly, Ray; Rodrigues, Jeremy; Yates, Paul A ; Arulananda, Surein; Parakh, Sagun |
| 2 | 13-Nov-2023 | Antibody drug conjugates for glioblastoma: current progress toward clinical use. | Gan, Hui K ; Parakh, Sagun ; Osellame, Laura D; Cher, Lawrence M ; Uccellini, Anthony; Hafeez, Umbreen ; Menon, Siddharth; Scott, Andrew M |
| 3 | 1-Nov-2023 | PD-L1 PET imaging in patients with NSCLC: Preliminary results of the ImmunoPET Phase 0 study. | Hegi-Johnson, Fiona; Rudd, Stacey E; Wichmann, Christian W; Akhurst, Tim; Roselt, Peter; Sursock, Sandra; Trinh, Jenny; John, Thomas ; Devereux, Lisa; Donnelly, Paul S; Hicks, Rodney J; Scott, Andrew M ; Steinfort, Daniel; Fox, Stephen; Blyth, Benjamin; Parakh, Sagun ; Hanna, Gerard G; Callahan, Jason; Burbury, Kate; MacManus, Michael |
| 4 | Aug-2023 | Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy. | Wang, Yang; Mathai, Jared; Alamgeer, Muhammad; Parakh, Sagun ; Paul, Eldho; Mitchell, Paul L R ; Arulananda, Surein |
| 5 | 31-Jul-2023 | Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer. | Poh, Ashleigh; Sammour, Abdelaziz; Mathai, Jared; Peverall, Joanne; Van Vliet, Chris; Asadi, Khashayar ; Parakh, Sagun |
| 6 | Apr-2023 | LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC. | Alexander, Marliese; Wei, Joe; Parakh, Sagun ; John, Thomas ; Kao, Steven; Nagrial, Adnan; Bowyer, Samantha; Warburton, Lydia; Moore, Melissa; Hughes, Brett G M; Clay, Timothy D; Pavlakis, Nick; Solomon, Benjamin J; Itchins, Malinda |
| 7 | 2023 | Editorial: Overcoming drug relapse and therapy resistance in NSCLC. | Parakh, Sagun ; Leong, Tracy L ; Best, Sarah A; Poh, Ashleigh R |
| 8 | Dec-2022 | A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. | Itchins, Malinda; Ainsworth, Hannah; Alexander, Marliese; Dean, Samantha; Dharmaraj, Devi; Pavlakis, Nick; Clarke, Stephen J; Brown, Chris; Torres, Javier; Saqib, Ayesha; Ladwa, Rahul; O'Byrne, Kenneth; Moore, Melissa; Yip, Po Yee; Solomon, Ben; John, Tom ; Kao, Steven; Mitchell, Paul L R ; Parakh, Sagun |
| 9 | 18-Nov-2022 | ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. | Hegi-Johnson, Fiona; Rudd, Stacey E; Wichmann, Christian; Akhurst, Tim; Roselt, Peter; Trinh, Jenny; John, Thomas ; Devereux, Lisa; Donnelly, Paul S; Hicks, Rod; Scott, Andrew M ; Steinfort, Daniel; Fox, Stephen; Blyth, Benjamin; Parakh, Sagun ; Hanna, Gerard G; Callahan, Jason; Burbury, Kate; MacManus, Michael |
| 10 | 22-Aug-2022 | Correction to: Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review. | Gunjur, Ashray ; Balasubramanian, Adithya ; Hafeez, Umbreen ; Menon, Siddharth; Cher, Lawrence M ; Parakh, Sagun ; Gan, Hui K |
| 11 | 6-Aug-2022 | Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review. | Gunjur, Ashray ; Balasubramanian, Adithya ; Hafeez, Umbreen ; Menon, Siddharth; Cher, Lawrence M ; Parakh, Sagun ; Gan, Hui K |
| 12 | Aug-2022 | A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. | Gan, Hui K ; Parakh, Sagun ; Lee, Fook-Thean; Tebbutt, Niall C ; Ameratunga, Malaka; Lee, Sze Ting ; O'Keefe, Graeme J; Gong, Sylvia J; Vanrenen, Christine; Caine, Jaren; Giovannetti, Mara; Murone, Carmel ; Scott, Fiona E; Guo, Nancy; Burvenich, Ingrid J G; Paine, Cameron; Macri, Mary J; Kotsuma, Masakatsu; Senaldi, Giorgio; Venhaus, Ralph; Scott, Andrew M |
| 13 | Aug-2022 | Adult medulloblastoma in an Australian population. | Parakh, Sagun ; Davies, Amy; Westcott, Kerryn; Roos, Daniel; Abou-Hamden, Amal; Ahern, Elizabeth; Lau, Peter K H; Cheruvu, Sowmya; Pranavan, Ganesalingam; Pullar, Andrew; Lynam, James; Gzell, Cecelia; Whittle, James R; Cain, Sarah; Inglis, Po-Ling; Harrup, Rosemary; Anazodo, Antoinette; Hovey, Elizabeth; Cher, Lawrence M ; Gan, Hui K |
| 14 | May-2022 | Primary CNS lymphoma in the real world-Opportunities for improved outcomes in different health settings | Parakh, Sagun ; Gan, Hui K |
| 15 | 18-Apr-2022 | Lung cancer in non-smokers: a diagnosis of increasing importance. | Dean, Samantha; Lennox, Rachel; Senko, Clare ; Parakh, Sagun |
| 16 | 11-Mar-2022 | Radiolabeled Antibodies for Cancer Imaging and Therapy. | Parakh, Sagun ; Lee, Sze Ting ; Gan, Hui K ; Scott, Andrew M |
| 17 | 3-Mar-2022 | The systemic management of central nervous system metastases and leptomeningeal disease from advanced lung, melanoma, and breast cancer with molecular drivers: An Australian perspective. | Senko, Clare ; Gunjur, Ashray ; Balasubramanian, Adithya ; Gan, Hui K ; Parakh, Sagun ; Cher, Lawrence M |
| 18 | 2022 | Antibody-drug conjugates: beyond current approvals and potential future strategies. | Menon, Siddharth; Parakh, Sagun ; Scott, Andrew M ; Gan, Hui K |
| 19 | 11-Dec-2021 | Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities. | Parakh, Sagun ; Ernst, Matthias ; Poh, Ashleigh R |
| 20 | 3-Dec-2021 | Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them? | Parakh, Sagun ; Nicolazzo, Joseph; Scott, Andrew M ; Gan, Hui K |